Heterogeneity within and across tumours is increasingly recognized as a critical factor that limits therapeutic progress for many cancers. Key studies reported in 2014 describe previously unappreciated patterns of geographical and temporal heterogeneity for glioblastoma (the most-common primary CNS tumour in adults), with important implications for ongoing therapeutic studies evaluating molecular targeted therapies.
This is a preview of subscription content, log in via an institution to check access.
References
Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396–1401 (2014).
Johnson, B. E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343, 189–193 (2014).
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98–110 (2010).
Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009).
Taal, W. et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 15, 943–953 (2014).
Chinot, O. L. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709–722 (2014).
Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699–708 (2014).
Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).
Phillips, H. S. et al. Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB]) [abstract]. J. Clin. Oncol. 32 (Suppl.), a2001 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.A.R. has served as a consultant and received honoraria from Amgen, Apogenix, EMD Serono, Genentech/Roche, Merck/Schering-Plough, Momenta Pharmaceuticals, Novartis and Stemline Therapeutics. P.Y.W. has served as a consultant and received honoraria from Abbvie, Celldex, Foundation Medicine, Genentech/Roche, Novartis, Momenta Pharmaceuticals and Sigma Tau.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Reardon, D., Wen, P. Unravelling tumour heterogeneity—implications for therapy. Nat Rev Clin Oncol 12, 69–70 (2015). https://doi.org/10.1038/nrclinonc.2014.223
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.223
- Springer Nature Limited
This article is cited by
-
miR-939, as an important regulator in various cancers pathogenesis, has diagnostic, prognostic, and therapeutic values: a review
Journal of the Egyptian National Cancer Institute (2024)
-
Treatment with quercetin increases Nrf2 expression and neuronal differentiation of sub ventricular zone derived neural progenitor stem cells in adult rats
Molecular Biology Reports (2023)
-
Elevated GIGYF2 expression suppresses tumor migration and enhances sensitivity to temozolomide in malignant glioma
Cancer Gene Therapy (2022)
-
Fear stress promotes glioma progression through inhibition of ferroptosis by enhancing FSP1 stability
Clinical and Translational Oncology (2022)
-
Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas
Cell Death & Disease (2020)